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In this paper we are concerned with the following question: Are the benzyl- 
penicilloyl and the benzylpenicillenate groups specific determinants of allergic 
reactions to benzylpenicillin in man?  1 Since simple organic molecules combine 
covalently with proteins as a  preliminary step in the induction  of the hyper- 
sensitive state, it seems clear that penicillin itself, which is incapable of reacting 
in the required manner with protein, must be regarded as a precursor of some 
derivative which possesses this necessary capacity. Penicillenic acid could well 
be the  derivative in  question  since it forms spontaneously and  readily from 
penicillin in neutral aqueous solution and is a highly reactive molecule capable 
of coupling with protein sulfhydryl and amino groups forming S-penicillenate 
and N-penicilloyl substituents, respectively (1, 2). Moreover, penicillenate- and 
penicilloyl-protein conjugates, prepared in vitro and injected into experimental 
animals, have  been  shown  to  be  potent  antigens  (1).  Elicitation  of  wheal- 
and-erythema responses in humans with well documented histories of penicillin 
hypersensitivity seemed to offer the most direct means for evaluating the de- 
terminant role of penicillenate and penicilloyl groups. Our preliminary studies 
in man using penicilloyl- and penicillenate-proteins as test reagents showed an 
encouraging correlation between positive wheal-and-erythema responses and a 
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history of penicillin hypersensitivity. Before extending these observations to a 
larger population  it  seemed prudent,  however,  to  develop skin  test reagents 
which  are  as  effective as  the  protein  conjugates  but  which  are  incapable  of 
inducing antibody formation to these penicillin derivatives. The feasibility of 
preparing reagents which meet these requirements  has been pointed out  in  a 
companion paper with reference to the dinitrophenyl system (4). 
In  the  present  paper  we  have  examined  a  series  of penicillin  derivatives 
with respect to their propensity for stimulating antibody production in guinea 
pigs and their effectiveness in eliciting immediate type allergic skin responses 
in guinea pigs and in humans.  Among the penicilloyl derivatives, penicilloyl- 
polylysine proved to be the most promising reagent for skin testing because of 
its effectiveness as an elicitor in guinea pig passive cutaneous anaphylaxis and 
lack of capacity to induce detectable antibody formation, specific for the penicil- 
loyl group. In respect to the penicillenate derivatives, a satisfactory replacement 
for the protein conjugate has not been prepared. The results of skin testing over 
1200 human subjects in a  selected population with a  high incidence of allergy 
to  penicillin  indicates  that  sensitivity to  the  penicilloyl  determinant  is  very 
common in human beings who are allergic to penicillin. Sensitivity to the peni- 
cillenate  determinant  also  commonly occurs  but  with  a  considerably  lower 
frequency.  In  this  study  specific  inhibition  of  positive  wheal-and-erythema 
responses  (5)  with  unifunctional  penicilloyl  and  penicillenate  haptens  has 
proven of considerable value in establishing confidence in the specificity of the 
human skin responses and in the identification  of the determinant groups in- 
volved. 
Materials and Methods 
Antigens,  tIaptens,  and Rabbit Antisera.--In preceding papers (I, 6) we have described the 
preparation of penicilloyl- and penicillenate-proteins,  bifunctional and unifunctional haptens, 
penicilloyl-polylysines, and  rabbit  antiserum  specific for  the  penicillenate and  penicilloyl 
determinants3 
6-aminopenicillanic acid and benzylpenicillin were generously furnished by Chas. Pfizer 
and Co., Brooklyn, New York. 
Immunogenicity.--Each  of the derivatives tested for capacity to induce antibody formation 
(Table I) was given to a group of 5 guinea pigs. Each animal received 1 mg of test material 
in Freund's adjuvant, distributed among the foot-pads (7, 8). Sera obtained 2 weeks  later were 
assayed for antibody activity by passive cutaneous anaphylaxis in guinea pigs, as described 
by Ovary (9) and in the accompanying  paper (4). 
Abbreviations: HSA, human serum albumin; B3~G, bovine gamma globulin; H"/G, human 
gamma globulin; penicillenate S--B7G and  penicillenate S--HSA, penicillenate conjugates 
prepared by reaction of penicillenic acid with Bh'G and HSA previously treated with N-acetyl- 
DL-homocysteine-thiolactone in  order  to  increase sulfhydryl  content;  bis-PNCE-MMD, 
3,6-bis-(penicillenate-mercurimethyl)-dioxane; penicillamine S-HSA, the  product  obtained 
by coupling penieillamine to HSA previously thiolated by reaction with N-acetyl-DL-homo- 
cysteine-thiolactone. C.  W.  PARK_ER~ J.  SttAPIRO~  M.  KERN~  AND  H.  N.  EISEN  823 
Purification of Anti-Penicillenate Antibody.--Antibody  specific for the penicillenate group 
was recovered in purified form by 2 different methods from washed specific precipitates formed 
at equivalence with rabbit anfi-penicillenate serum and penicillenate S--B3,G (33 penicilienate 
groups per molecule of B'yG). In the 1st method, the specific precipitate was dissolved in 
0.05 ~  ice cold acetic acid and 0.8 volumes of ice cold 2-N HC] were added. The suspension 
was centrifuged immediately at 11,0130 g for 3 minutes and the supernatant was dialyzed at 
4°C  against 0.15 ~  NaCI-0.01  u  phosphate, pH  7.5,  or was first partially neutralized with 
phosphate and then dialyzed. By this procedure antibody was recovered in 40 to 50 per cent 
yield and was 88 per cent precipitable with penicillenate S--B'yG. 
In the second procedure, the specific precipitate was dissolved in ice cold 0.05 ~t acetic 
acid and 1/4 volume of ice cold 5 ~  NaC1 was added. Mter centrifugation at 11,1300 g for 3 
minutes, the supernatant was removed and dialyzed without delay at 4°C  against 0.15 
NaC1--0.01  M phosphate, pH  7.4.  Recovery:  20 per cent.  Precipitability with penicillenate 
S-BTG was 77 per cent. 
Both purified antibody preparations were titrated at 30°C with p-penicillenate-mercuri- 
benzoate by the fluorometric method previously described (10). In both cases, the association 
constant found was 3 X  106 liters per mole. Under the titration conditions used, the antibody 
concentration was 0.24 mg per ml, and 55 per cent of the antibody sites were titrated, assum- 
ing (a) that the protein preparations were 90 per cent pure,  (b) that there are 2 combining 
sites per antibody molecule and  (c) that the antibody molecular weight is 160,1300. Despite 
the severity of the treatment of the antibody with 0.9 r~ tIC1, papain digestion (11)  of the 
purified product yielded a soluble fraction in 50 per cent yield which did not precipitate with 
antigen, but which was immunologically active as evidenced both by specific inhibition of 
precipitation and by ftuorometric titration. Moreover, a small amount of crystalline material 
resembling Porter's fraction III (11)  was obtained, approximately in 7 per cent yield. 
"y-Globulin Fractions of tturnan  Serum.----%Globuhns were precipitated from human sera 
at 4°C with ammonium sulfate, pH 7.4,  at a  final concentration of 1.75 ~. The precipitates 
were washed twice with 1.75 ~  ammonium sulfate, dissolved in 0.15 M NaC1-0.01 ~r phosphate, 
pH 7.4,  and dialyzed for several days in the cold against the latter solvent. 
Skin  Testing in Human Subjects.--Materials  used  for  testing were  diluted with 0.15  ~, 
NaC1-0.01 M  phosphate, pH 7.4. The final concentration of the stock solutions was determined 
following sterilization by filtration through Seitz filters. When penicillin and 6-aminopenicil- 
lanic acid were used, the solutions were freshly prepared. The penicilloyl-polylysine used for 
skin testing was the preparation designated B  in the companion paper (6), unless otherwise 
specified. 
Intradermal injections were made with a 26 gauge needle, the volume injected being gener- 
ally about 0.07 ml. The size of the initial bleb was outlined on the skin for reference purposes, 
and the test sites were examined every 5 minutes for 20 minutes. Mter 20 minutes the area 
of urticaria and erythema were marked with a pen and transferred to a transparent tape as a 
permanent record (5). Subjective symptoms of the subject and impressions of the observers 
also  were  recorded. 
Preliminary intradermal injections in normal human subjects showed the following com- 
pounds to be non-irrltant: Penicilloyl-polylysine,  3 penicillenate S-HSA, e-penicilloyl-amino- 
caproate,  bis-penicilloyl-cystine, ¢-penilloaldehyde-aminocaproate, S-(N-ethylsuecinimidyl)- 
penicillenate, p-Penicfllenate-mercuribenzoate gave a  slight but significant reaction in 4 out 
of  7 apparently normal subjects. 
Since a substantial number of the individuals evaluated in this study gave unusually marked 
3 The non-specific urticarial responses produced in human skin by DNP-polylysines were 
eliminated by succinylation (4). The non-irritancy of peniellloyl-polylysines is probably due 
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skin responses,  the system employed elsewhere  (5) for scoring wheal-and-erythema responses 
has been modified  as follows:  +, an ambiguous response, the wheal being only slightly larger 
than the initial injection bleb; 1+, a distinctly positive response, wheal <8 mm in diameter; 
2+, wheal, 8 to 12 mm in average diameter; 3+, wheal, 12 to 20 mm in average diameter; 
4+,  wheal  >20 mm in average diameter. 
Human Subjects.--More than 90 per cent of the subjects tested were patients at the Venereal 
Disease Clinic of the St. Louis City Health Division. Many of the patients had received mul- 
tiple courses of penicillin therapy over a period of years, with an average of about 3 penicillin 
courses per year per patient. Patients with medical indications for penicillin treatment were 
routinely tested with penicilloyl-polylysine regardless of their history in respect to previous 
allergic reactions to penicillin. Skin testing with penicillenate S-HSA was limited to persons 
with a history of previous allergic reactions to penicillin, and those in whom a positive skin 
reaction had been evoked with penicilloyl-polylysine. 
A history of penicillin allergy was considered reliable if any of the following symptoms had 
occurred within 1 week of penicillin treatment, provided no other drug had been given: anglo- 
neurotic edema, urticaria, maculopapular eruption, or anaphylaxis. At least three-fourths of 
the persons in the group with a positive history of penicillin sensitivity had been attending 
the Venereal Disease Clinic at the time their allergic reactions had occurred, and the diagnosis 
of penicillin allergy had been corroborated by an attending physician. In perhaps one-tenth 
of the patients listed in this group there was, however, serious doubt as to the validity of their 
history of penicillin hypersensitivity. The majority of sensitive subjects had had their reac- 
tions to penicillin within the preceding 2 years, but in a few instances more than  10 years 
had elapsed. 
In the group with a history of penicillin allergy, penicillin was not given therapeutically. 
In the group with a  negative history for penicillin hypersensitivity,  those with a  negative 
skin response to penicilloyl-polylysine were treated with parenteral penicillin, as required by 
their disease. 4 Many of the individuals who had negative histories for penicillin sensitivity 
but  positive wheal-and-erythema  skin  responses  to penicilloyl-polylysine were  also  treated 
therapeutically with penicillin: the dosage schedule and general procedures in this group were 
dictated by the specific medical condition under treatment. 
All subjects who were given penicillin were instructed to report to the clinic any symptoms 
of penicillin allergy. Moreover, as a consequence of the medical follow-up required to insure 
eradication of disease,  many of the tested subjects were seen at a later time, when additional 
specific inquiries were made with reference to symptoms of penicillin allergy. Previous experi- 
ence at  this clinic indicated  that  individuals who developed untoward  symptoms returned 
in large measure for diagnosis and treatment of their own volition, even without the specific 
instructions noted above. 
Transfer of Purified Rabbit Anti-Penicillenate Antibody to Human Skin.--The procedures 
used  to sensitize human  skin sites with purified rabbit  antibody,  and  to evoke wheal-and- 
erythema responses  in such sites,  have been described previously (5).  When "},-globulin frac- 
tions of human sera were used to sensitize skin sites in normal subjects, the procedure followed 
was unchanged, except that the sensitized sites were not tested with antigens until 1 to 5 days 
later. 
RESULTS 
The  capacity  of various  penicillenate  and  penicilloyl derivatives  to  induce 
antibody  formation  are  given  in  Table  I.  Only  the  protein  conjugates  were 
4 The penicillin preparations usually employed therapeutically were benzathine-penicillin 
G  (N, N~-dibenzylethylenediamine dipenicillin G) and penicillin-aluminum monosterate in 2 
per cent sesame oil. C.  W.  PARKER,  J.  SHAPIRO~  M.  KERN~  AND  H.  N.  F  ISEN  825 
effective. The bivalent derivatives and penicilloyl-polylysine had no detectable 
immunogenic  capabilities.  As  noted  in  the  preceding  paper  (6),  passive cu- 
taneous anaphylaxis responses, with homologous antisera, were evoked feebly 
with  bifunctional  derivatives  (bis-penicillenate-MMD  and  bis-penicilloyl- 
cystine) and intensely with peniciUoyl-polylysine. 
In human skin sites prepared passively with purified rabbit anti-penicillenate 
antibody,  wheal-and-erythema  responses  were  not  evoked  with  bis-penicil- 
lenate-MMD,  using  40  m/~eq  penicillenate,  but  with  400  m~eq positive  re- 
sponses were obtained. Penicillenate S-HSA elicited a positive response in these 
TABLE  I 
Antibody Formation Induced by Various Penidlloyl and Pen,iciUenate Derivatives as Indicated 
by  Passive  7utaneous Anaphylaxis  in  the  Guinea Pig 
Skin  responses~  in  guinea  pig  No. 
Serum obtained  from  guinea  pigs 
injected  with* 
1  2  3  4  5  6  7  8  9  10 
0  0  0  0  0 
3+  4+  3+  4+  4+ 
0  0  0  0  -- 
0  0  0  0  0 
0  0  0  0  0 
4+  4+  4+  4+  4+ 
bis-PNCE-MMD 
Penicillenates0 S-B3,G§ 
bis-Penicilloyl-cystine 
Penicilloyl-polylysine A 
Penicilloyl-polylysine B 
PeniciUoyho-B~G§ 
* Each guinea pig received 1 mg of one of the substances listed in Freund's adjuvant  (see 
Materials  and  Methods).  Each  recorded response corresponds to  an  individual  animal's 
serum. 
:~ Penicillenate S-HSA and penicilloyl-H~,G  in 1 mg amounts were used to evoke responses 
with sera from animals immunized with penicillenate and penicilloyl derivatives, respectively. 
§ All  sera  from  animals injected  with  peniciUenate S--B3.G and  penicilloyl-B-iG gave 
strongly positive ring precipitin tests with penicillenate S-HSA and penieilloyl-H~,G  respec- 
tively, using 50 #g antigen/ml.  All other sera gave negative ring precipitin tests. 
passively prepared sites when injected  at a  level corresponding  to  5.6  m~eq 
penicillenate.  Thus,  the bivalent compound was much less effective than the 
protein  conjugate  as  an  elicitor  of  the  wheal-and-erythema  response,  even 
allowing  for  the  fact  that  the  antibody  specificity in  this  instance  may be 
directed in part toward the N-acetyl-wL-homocysteine groups which are present 
in  the  protein  conjugate but  not  in  the  bifunctional  penicillenate  derivative 
(6). 
1250  individuals  were skin tested with penicilloyl-polylysine, and of these, 
64 were also tested with penicillenate S-HSA. Of the entire group, 15 subjects 
with well established penicillin allergy have been studied in detail. The responses 
in 5 of these latter subjects, summarized in Tables II to VI, will serve to illus- 
trate the  essential features of the responses in  the hypersensitive population 
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Penicilloyl-polylysine  and penicilloyl-protein  conjugates  were about  equally 
effective  in  eliciting  wheal-and-erythema  responses,  and  were  clearly  very 
much  more effective than  bis-penicilloyl-cystine  (see Table  II, subject  T.  S.; 
similar  results  were  obtained  in  2  other  individuals).  The  failure  of penicil- 
lenate  S-HSA  to evoke a  response in  subject  T.  S.  (Table II)  is striking:  1.5 
m#eq penicillenate  groups were ineffective although  the corresponding  penicil- 
loyl  derivatives  were  reactive  when  only  0.0005  m/~eq  of  penicilloyl  was  in- 
jected.  2  other  individuals  who  reacted  positively  to  penicilloyl-polylysine 
TABLE  II 
Wheal-and-Erythema Responses in a Penicillin-Sensitive Subject.* Titration of Reagents 
Test No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Substances injected 
Penicillenate  S--HSA 
Penicilloyl-HTG 
Penicilloyl-polylysine  A 
Penicilloyl-polylysine  B 
Penicilloyl-BTG 
Penicillamine  S--HSA 
bis-penicilioyl cystine 
Quantity 
(As total  (As penicilloyl 
weight)  3r penicillenate) 
#g  m#eq 
6.6  1.5 
3.8  0.4 
0.38  0.04 
0.038  0.004 
O. 0048  O. 0005 
0.0005  0.0005 
0.00036  0.0005 
0.0015  0.0005 
0.002 
0.024  0.05 
0.0024  0.005 
0.00024  0.0005 
Result 
0 
4+ 
4+ 
3+ 
2+ 
2+ 
2+ 
2+ 
0 
1+ 
4- 
0 
* Subject:  T.  S.  For  passive transfer with  subject's  serum protein (v-globulin fraction) 
and hapten inhibition  of transfer reaction,  see Table VI. 
were  tested  with  this  derivative  after  it  had  been  treated  with  2-mercapto- 
ethanol  in  order  to  eliminate  penicillenate  groups  (6):  the  mercaptan-treated 
penicilloyl-polytysine  derivative  and  the  untreated  derivative  were  equally 
effective. 
Approximately 50 per cent of all individuals with positive cutaneous responses 
to penicilloyl-polylysine  failed  to  react  to  penicillenate  S-HSA,  although  the 
comparison in the group as a whole was generally made with equivalent amounts 
of penicilloyl and penicillenate groups, rather than with the 3000-fold difference 
illustrated  in  Table  II. 
Penicillenate  and penicilloyl  conjugates  are both  contaminated  by a  signifi- 
cant number of penamaldate or penilloaldehyde groups as judged by absorption 
at 280 m#  (6).  The penamaldate:penicillenate  ratio  is greater in penicillenate 
S-HSA  than  is  the  penamaldate:penicilloyl  ratio  in  penicilloyl-polylysine. C. W. PARKER~ J.  SHAPIRO,  ]W.  KERN,  AND  H.  N. EISEN  827 
Hence, in testing with equimolar amounts  of penicilloyl and penicillenate  con- 
jugates  (penicilloyl-polylysine  and penicillenate  S-HSA,  respectively),  a  nega- 
tive response to the penicillenate-protein conjugate might be construed to mean 
that  groups  of  the  penamaldate-penilloaldehyde  type  make little  or  no  con- 
tribution  to the  response  to penicilloyl-polylysine.  As pointed  out  in the pre- 
TABLE III 
Hapten Inhibition  of Wheal-an&Erythema  Response  to  Penicilloyl-Polylysine  in  Penicillin- 
Sensitiz~e Subjects 
Subject 
J.A. 
P° L. 
Tes~ 
No. 
1 
2 
3 
4 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Substances  injected 
Penicilloyl-p olylysine B 
PenicilLoyl-polylys'me B + 
c-penicilloyl-aminocapr oate 
Penicilloyl-polylysine  B + 
c-penilloaldehyde-aminocapr oate 
Penicitlenate  S--HSA 
Penicilloyl-polylysine  B 
PeniciUoyl-polylysine  B -t- 
¢-penicilloyl-aminocaproat e 
Penicilloyl-polylysine  B q- 
e-penicilloyl-aminocaproat e 
Penicil|oyl-polylysine B + 
~-penlcilloyl-aminocaproate 
PeniciUoyl-polylysine  B -t- 
•  -peaUloaldehyde-aminocapr oate 
Penicilloyl-polylysine  B -I- 
¢-penilloaldehyde-aminocaproate 
PeniciUoyl-polylysine  B + 
•  -penflloaldehyde-aminocapr oate 
Penicilloyl-polylysine  B + 
N-ethylsuccinimidyl-penicillenate 
PenidUenate  S-HSA 
BenzylpeniciUiu 
Quantity (as 
penicilloyl or 
penicillenate) 
m~eq 
4 
4 
40O 
4 
400 
4 
0.7 
0.7 
I00.0 
0.7 
25.0 
1.7 
100.0 
0.7 
100.0 
0.7 
25.0 
1.7 
I00.0 
0.7 
90.0 
3.5 
2.0 
Result 
4+ 
I to2+ 
0 
1  to2+ 
4+ 
0 
+ 
,4- 
O 
I+ 
-4- 
4+ 
0 
0 
ceding  paper,  however,  the  nature  of the  penamaldate  substitueuts  in  these 
2 kinds of conjugates  may well be different  (6). 
Cutaneous  responses  to  penicilloyl-polylysine  were  readily  inhibited  by 
¢-penicilloyl-amlnocaproate,  provided a  sufficient excess of the latter univalent 
hapten  was used  and  the level of penicilloyl-polylysine  employed gave a  2  to 
3-t-  response  rather  than  the  maximal  4-t-  response.  Partial  or  complete  in- 
hibition  with  this  combination  of univalent  hapten  and penicilloyl-polylysine 
was obtained in 39 out of the 43 subjects in whom it was attempted  (i.e., gen- 828  PENICILLIN  ALLERGY  IN  HUMAN  BEINGS 
erally with penicilloyl-polylysine as 4  mgeq penicilloyl and 400  mgeq  e-peni- 
cilloyl-aminocaproate). In 4  subjects, little or no inhibition was obtained; but 
in  these no  attempt  was  made  to reduce  the penicilloyl-polylysine to  a  level 
more favorable for demonstrating inhibition by the univalent hapten,  e-Peni- 
cilloyl-aminocaproate was  clearly more effective as an  inhibitor in some sub- 
TABLE IV 
tlapten Inhibition of Wheal-and-Erythema  Response  to Penicilloyl-Polylysine  and 
Penlcillenate S-HSA in a Penicillin-Sensitive  Subject* 
Quantity (as 
Test No.  Substances injected  penicilloyl or  Result 
penicilleuate) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
Penicilloyl-polylysine  B 
Penicilloyl-polylysine  B + 
¢-penicilloyl-aminocaproate 
Penicilloyl-polylysine  B + 
e-penilloaldehyde-aminocaproat e 
Penicilloyl-polylysine  B + 
N-ethylsuccinimidyl-penicillenate 
Penicilloyl-polylysine  B + 
N-ethylsuccinimidyl-penicillenate 
Penicillenate S-HSA 
Penicillenate  S-HSA + 
~-penicilloyl-aminocaproate 
Penicillenate  S-HSA + 
epenilloaldehyde-aminocapr  oate 
Penicillenate S-HSA + 
N-ethylsuccinimidyl-penicillenate 
Penicillenate S-HSA + 
N-ethylsuccinlmidyl-penicillenat  e 
Penicillenate  S-HSA + 
p-penicillenate-mercuribenzoat e 
p-Penicillenate-inercuribenzoat  e 
bis-Penicillenat  e-MMD 
Benzylpenicillin 
mtzeq 
0.7 
0.7 
100.0 
0.7 
I00.0 
0.7 
360.0 
0.7 
90.0 
0.7 
0.7 
400.0 
0.7 
400.0 
0.7 
360.0 
3.5 
360.0 
0.7 
400.0 
400.0 
1.2 
2.0 
3+ 
0 
0 
2+ 
3+ 
3+ 
2+ 
2+ 
0 
0 
2+ 
2+ 
0 
1+ 
* Subject: S. G. 
jects than in others. For example, in subject J. R. (not illustrated in a  Table ), 
complete  inhibition  of  the  cutaneous  response  to  penicilloyl-polylysine was 
produced by this univalent hapten in 35-fold molar excess over the penicilloyl 
groups  in  the polylysine derivative; and  considerable inhibition with  hapten 
excesses of this order of magnitude have been  the rule where  titrations were 
carried out, rather than the exception. With subject J. A., however, a  100-fold 
molar excess of e-penicilloyl-aminocaproate over the penicilloyl residues in the 
polylysine  conjugate  only  partially  inhibited  the  cutaneous  response  (see C. W.  PARKER, ~. SHAPIRO, M.  KERN, AND H. N. EISEN  829 
Table III); in this same subject, epenilloaldehyde-aminocaproate completely 
inhibited  the  response  to penicilloyl-polylysine. As  a  general rule,  however, 
penilloaldehyde-aminocaproate was about equal in effectiveness to penicilloyl- 
aminocaproate in respect to inhibition of responses evoked with peniciUoyl- 
polylysine. Quantitative comparison between these two unifunctional inhibitors 
has not been attempted on an extensive scale since detailed interpretation of 
the inhibition is limited by a number of unevaluated side reactions; for example 
TABLE V 
Hapten Inhibition of Wheal-and-grythema  Response to Penidlloyl--Polylysine  and 
Penicillenate S-HSA in a Penicilbin-Sensltive Subject* 
Quantity (as 
Test No.  Substances injected  peniciUoyl  or  Result 
peniciUenste) 
Penicilloyl-polylysine  B 
PeniciUoyl-polylysine  B + 
¢-penicilloyl-aminocaproate 
Penicilloyl-polylysine  B _i_ 
c-penilloaldehyde-aminocapr  oate 
Penicilloyl-polylysine  B -4- 
N-ethylsuccinimidyl-penicillenate 
Penidllenate S-HSA 
PeniciUenate S-HSA "4- 
•  -peniciUoyl-aminocaproat  e 
PeniciUenate S-HSA -b 
c-penilloaldehyde-aminocapr  oate 
Penicillenate S--HSA -F 
N-ethylsuccinimidyl-penicillenate 
Penicillenate S-HSA -5 
p-penicillenate-mer  curibenzoat  e 
mtteq 
0.7 
0.7 
400,0 
0,7 
400.0 
0.7 
360.0 
0.7 
0.7 
400.0 
0.7 
400.0 
0.7 
360.0 
0.7 
400.0 
2+ 
0 
0 
2+ 
2+ 
1+ 
-4- 
2+ 
2+ 
* Subject: J. M. 
(a) the possibility that the penilloaldehyde hapten might react with free amino 
groups in the skin, and (b) the possibility that one or both of these inhibitors 
are bound to a considerable degree by proteins in skin, e.g., by serum albumin. 
As expected (6), unifunctional penicillenate haptens are, at best, poor inhibitors 
of  responses  evoked by penicilloyl-polylysine (see  Tables  III,  IV,  and  V). 
6-aminopenicillanic  acid  failed also  to  inhibit  responses  to  peniciUoyl-poly- 
lysine in each of 4 subjects in whom this was tested (see also Fig. 5 in reference 
6). 
Ten subjects  have been  tested  in  respect  to  the  capacity of S-(N-ethyl- 
succinimidyl)-penicillenate to  inhibit  wheal-and-erythema  responses  evoked 
with penicillenate S-HSA. In 4 of the 10, inhibition was essentially complete, 
in 3 it was partial, and in 3 there was little or no inhibition. In 2 of 4 subjects 830  PENICILLIN  ALLERGY  IN  HUMAN  BEINGS 
with  complete  inhibition  by  S-(N-ethylsuccinimidyl)-penicillenate,  hapten 
inhibition  of  the  response  to penicillenate S-HSA  was  also] attempted  with 
e-penicilloyl-aminocaproate  and  e-penilloaldehyde-aminocaproate  and,  as 
expected, the latter haptens were ineffective inhibitors  (see illustrative group 
of responses in Table IV, S. G.). The responses of J. M., however, (Table V), 
illustrate  the  converse  situation,  where  unifunctional  penilloaldehyde  and 
penicilloyl haptens  inhibited  more  effectively than  S-(N-ethylsuccinimidyl)- 
penicillenate. Thus despite its promise as a monospecific test reagent for peni- 
cillenate sensitivity as indicated by passive cutaneous anaphylaxis studies (6), 
TABLE VI 
Wheal-and-Erythema Responses Following Passive  Transfer  of Serum  Globulins from  a 
Penicillln-Sensitgve Subject* 
Quantity (as  Result  Test No.  Test substance  haptenic sites) 
Penicilloyl-polylysine  B 
Penicilloyl-polylysine  B + 
,-penicilloyl-aminocaproate 
Penicilloyl-polylysine  B -[- 
¢-peniciUoyl-aminocaproate 
Penicilloyl-polylysine  B -[- 
~-penilloaldehyde-aminocaproate 
bis-penicilloyl cystine 
Benzylpenicillin 
m~eq 
4 
4 
1040 
4 
104 
4 
40 
10 
3+ 
0 
0 
0 
-4- 
-4- 
Donor: T. S. (see  Table II for active responses  of this subject). 
Recipient: C. W. P. 
* Sites were prepared with 0.1 ml of a -r-globulin fraction containing 5 mg protein in 
0.15 M  NaCI-0.01 ~ PO4 buffer, pH 7.4. Sites were challenged 5 days later. 
it appears that contaminating groups of the penilloaldehyde-penamaldate type 
in  penicillenate  S-HSA  may  contribute  significantly  to  positive  responses 
evoked with this conjugate, at least in some human subjects. Positive reactions 
evoked in man with penicillenate S-HSA have been inhibited poorly with the 
unifunctional hapten p-penicillenate-mercuribenzoate, inhibition being obtained 
in only 4 out of the 22 subjects examined. In some instances, in fact, p-penicil- 
lenate-mercuribenozate seemed even to augment the response to penicillenate 
S-HSA despite the fact that in normal skin this unifunctional hepten is rela- 
tively inert. Moreover, even when p-penicillenate-mercuribenozate was given 
alone to some penicillin-sensitive individuals  it produced typical wheal-and- 
erythema responses (Table IV, subject S. G.). It is possible that the Hg-S bond 
in this hapten is cleaved in the skin by cutaneous sulfhydryl groups with the 
subsequent formation of protein-linked penicillenate which can then, in turn, C.  W.  PAP,.KER~ J.  SHAPIRO,  M.  KERN,  AND  H.  N.  EISEN  831 
evoke specific wheal-and-erythema responses.  The significant reaction blank 
in some normal subjects makes this possibility difficult to evaluate. 
Passive transfer to normal human skin of ~,-globulin fractions of sera of three 
penicillin-sensitive human subjects has been attempted. Transfer was success- 
ful in one instance, using the "r-globulin fraction from subject T. S. whose skin 
responses were summarized in Table II. As shown in Table VI, 5 days after 
skin sites in a  normal subject had been injected with about 5 mg "r-globulin 
from T.  S.,  injection of penicilloyl-polylysine evoked a  wheal-and-erythema 
response, and this response could be completely inhibited with e-penicilloyl- 
aminocaproate. 
TABLE  VII 
Correlation Between History of Previou~ Allergic  Reactions to Penicillin and  Wheal-and- 
Erytkema Responses  to  Penicilloyl-Polylysine  and  to  Penicillenate  S-HSA 
History 
Previous allergic reaction to 
peniciUin 
No previous allergic reaction 
to penicillin 
Response to 
Peniciiloyl-Polylysine  Penicillenate  S-HSA 
Positive 
45 
44 
Negative 
14 
1147 
[  In persons giving 
positive responses to 
[ ponicilloyl-polylysine 
Positive  Negative 
12  10 
12  12 
In persons  giving 
negative responses to 
peniciUoyl-polyiysine 
Posi!ve  Negative 
6 
12 
The results obtained thus far in screening 1250 subjects are summarized in 
Tables VII and VIII. Of the persons having a history of previous allergic reac- 
tion to penicillin approximately 75 per cent (45 of 59) had positive skin reac- 
tions to penicilloyl-polylysine.  On the other hand, only 4 per cent of individuals 
with no previous history of penicillin allergy gave positive skin reactions to this 
penicflloyl conjugate. About 50 per cent of individuals who gave positive skin 
responses  to penicilloyl-polylysine also gave positive responses  to penicillen- 
ate S-HSA. 
Of the  14 individuals with positive histories of previous penicillin allergy 
and negative skin responses to penicilloyl-polylysine, 6 were tested with peni- 
cillenate S-HSA, and none reacted (Table VII). 
Reactions to subsequent penicillin therapy in relation to skin test responses 
to penicilloyl-polylysine were particularly striking. In 1191 subjects without a 
previous history of penicillin allergy, 44 gave positive skin reactions to peni- 
cilloyl-polylysine (Table VII). Of these 44 individuals, 23  were treated with 832  PENICILLIN ALLERGY  IN IIUMAN BEINGS 
penicillin shortly after the skin test had been performed.  9 of these 23 persons 
exhibited  systemic allergic reactions  (Table  VIII). On the other hand,  of the 
1147 subjects in this group (i.e., with no history of previous penicillin allergy) 
with negative skin reactions to penicilloyl-polylysine, only 1 subject reacted to 
TABLE VIII 
Corrdation  between Wheal-and-Erythema  Responses  to  t'enicilloyl-Polylysine  and  Allergic 
Reactions to Subsequent Penici#in  Therapy  in Individuals  ~qCh No Previous History  of 
Penicillin Allergy 
Skin reaction to 
penicilloyl-polylysine B 
Positive 
Negative 
Response to penicillin therapy 
Allergic reaction 
9*,  :~ 
oil 
No allergic reaction 
14§ 
1146 
Incidence of 
allergic reaction 
~er Ce~t 
39 
<0.1 
* 4  non-fatal  anaphylactic  reactions;  1 immediate  urticarial  reaction;  4  late  urticarial 
reactions  (onset 4 to 48 hours after injection). 
4 of the 9 had been tested  with penicillenate  S-HSA: In 1 (anaphylactic  reaction),  a 
positive  wheai-and-erythema  response had  been obtained.  In 3  (late urticarial  reactions), 
the cutaneous reaction had been negative. 
§ 6 of the 14 were tested for hapten inhibition.  In 5 the response to penicilloyl-polylysine 
was inhibited by ~-penicilloyl-aminocaproate. 
]] There were actually 2 subjects with a negative history of previous penicillin allergy and 
a negative  skin test response to penicilloyl-polylysine who had systemic  allergic reactions 
to subsequent  penicillin therapy.  Further  evaluation,  however, provided  the basis for ex- 
cluding these 2 subjects from this category: thus, subject C. C. had an anaphylactic  reaction 
after  injection  of dicrysticin  (400,000 units  procaine penicillin plus 0.5  gm  streptomycin). 
Subsequently  intradermal  injection  of 3.5 #g streptomycin  produced  massive local edema 
and  urticaria  and  intradermal  tests  with penicilloyl-polylysine and  with  penicillenate  S- 
HSA were negative. Moreover, 1.2 million units penicillin given later,  therapeutically,  were 
tolerated  without  any reaction.  This subject's  reaction  to dicrysticin  was  presumably  due, 
therefore,  to streptomycin  rather  than  to penicillin. The 2nd  subject  in question  (S.  B.) 
had  known  systemic  lupus  erythematosis  and  developed urticaria,  arthritis,  and  fever  3 
days after  penicillin therapy.  On repetition  of the  skin  tests  after  the  systemic  reaction, 
positive  responses were evoked with penicilloyl-polylysine and penicillenate  S-HSA.  More- 
over, re-evaluation  of the history indicated  a probable penicillin reaction in the past. 
subsequent therapy, but on further investigation it seemed very likely that this 
reaction was due to streptomycin which had been included in the therapeutic 
injection (see footnote, Table VIII). There is, therefore, in individuals  with no 
previous  history  of penicillin  allergy more  than  a  400-fold difference  in  the 
incidence of systemic reaction  to penicillin  therapy between  those individuals 
who give positive wheal-and-erythema  responses  to penicilloyl-polylysine and 
those who do not. 
Ten of the subjects who gave positive skin responses to penicilloyl-polylysine C.  W.  PARKER,  J.  SItAPIRO,  x~.  KERN,  AND  H.  N.  EISEN  833 
were tested with penicillin; each test consisted of an intradermal injection of 
1 to 22 units of penicillin corresponding to about 2 to 40 m/~moles, or on a 
molar basis, 2 to 10 times more penicillin than the penicilloyl substituents in 
the  penicilloyl-polylysine tests  which  gave  strongly positive  responses.  9  of 
the  10  subjects  thus tested gave negative, or at most, feeble responses  (see 
Tables III, IV, VI for representative results). In I of these 10 subjects, who was 
tested with  11  m/anoles of penicillin O  (allylthiomethylpenicillin), a  strong 
reaction was obtained. Examination of the penicillin O solution revealed, how- 
ever, an absorbance of 0.050  at 322 m/~, corresponding to 0.13  m/zmoles peni- 
cillenic acid as a  contaminant in the intradermal injection. 
Out of the 1250 individuals who have so far been tested in the present work, 
only two systemic reactions to the skin tests have been observed.  The first 
occurred in a  subject (M. L.) who had received two intradermal injections of 
penicillenate S-HSA and one injection of penicilloyl-H-rG and within a  few 
minutes developed generalized itching and urticaria. The second systemic reac- 
tion occurred in a subject (D. W.) 48 hours after skin testing with penicillenate 
S-HSA and p-penicillenate-mercuribenzoate; it consisted of nausea, generalized 
itching, and a marked urticarial reaction at the skin test site which had been 
recorded initially as a  negative response. 
DISCUSSION 
Penicillin derivatives and dinitrophenyl derivatives exhibit striking simUari- 
ties in respect to dependency of their biological activities on molecular size, 
character,  and  multiplicity of  determinants  per  molecule:  (a)  Derivatives 
containing multiple determinant  groups  per  molecule  evoke  specific  wheal- 
and-erythema  responses  and  univalent  haptens  specifically  inhibit  these 
responses. (b) The polyfunctional polylysine derivatives are about as effective 
as the corresponding protein conjugates in elicifing the cutaneous responses. 
(c) Small bivalent derivatives, i.e.,  those with 2 determinants per molecule and 
molecular weight less  than 1500, are relatively ineffective elicitors of the cu- 
taneous responses;  moreover,  in  the  dinitrophenyl system these  derivatives 
give variable  responses  and  this variability seems  to  reflect dependency on 
antibody Mfinity (see reference 4). (d) In contrast to the well known effective- 
ness of protein  conjugates, small bivalent derivatives and multivalent poly- 
lysine conjugates fail to produce antibody in a  quantity suificient to be de- 
tectable  by  passive  cutaneous  anaphylaxis,  even  when  given  in  Freund's 
adjuvant. 
The  results  of  testing  over  1000 human  subjects  demonstrates  dearly  a 
striking correlation between penicillin allergy and specific cutaneous reactions 
to the penicilloyl and penicillenate determinants. Of the two, the responses to 
penicilloyl were the more frequent. Although hapten inhibition demonstrates 
clearly that the specificity of the wheal-and-erythema response to penicilloyl- 834  PENICILLIN ALLERGY  IN  HUMAN  BEINGS 
polylysine is directed towards the penicilloyl group, detailed evaluation of the 
contributions made by component segments of this group cannot yet be made. 
It is highly probable,  however, that C5-C  8, and the a-carbonyl and the lysyl 
side chain to which it is attached in amide linkage, are particularly significant 
(see reference 6, Fig.  1). Thus, penilloaldehyde-aminocaproate was ordinarily 
just as effective as penicilloyl-aminocaproate in inhibiting skin responses  to 
penicilloyl-polylysine, and  6-aminopenicillanic  acid  was  entirely ineffective. 
Similar results were obtained in vitro by hapten inhibition of the precipitation 
of rabbit antisera prepared against penicilloyl-proteins (6).  The contribution 
made by the various R  substituents in different penicillins (i.e.,  attached to 
C8; see reference 6, Fig. 1) must await further investigation, as with only rare 
exceptions in the present work all of the substances examined were derivatives 
of benzylpenicillin. 
The results obtained by hapten inhibition of skin responses to penicillenate 
S-HSA are less clear-cut with respect to establishing the nature of the deter- 
minants involved here. The few tests so far made with S-(N-ethylsuccinimidyl)- 
penicillenate  encourage  the  view  that  the  penicillenate group  is  the  major 
determinant in about one-half of the responses to penicillenate-proteins. The 
fact that in subject J. M. (Table V) skin responses to the latter conjugate were 
instead  inhibited  by  ~-penilloaldehyde-aminocaproate, suggests  that  substi- 
tuents of the penilloaldehyde-penamaldate type make a major contribution to 
skin reactivity to penicillenate S-HSA in some instances. As in the case of the 
responses  to  penicilloyl-polylysine, the  contribution  of  the  R  group  to  the 
responses  evoked with  penicillenate  S-HSA  will  have  to  await  study with 
derivatives made from penicillins other than benzylpenicillin. 
Since one-half of all humans who responded to penicilloyl-polylysine reacted 
also to penicillenate S-HSA, which lacks the penicilloyl group, it is apparent 
that determinants other than penicilloyl are frequently involved in penicillin 
allergy. Nevertheless, it is abundantly clear that all of the determinants for 
which there is now clear or suggestive evidence are formed by the reaction of 
penicillenic acid with proteins. Penicillenic acid appears,  therefore, to be the 
immediate precursor of the protein conjugates which induce antibody forma- 
tion and which elicit the allergic responses to penicillin. 
From the foregoing point of view the search for penicillins with little or no 
potential for inducing allergic reactions might well revolve about those which 
do not degrade to penicillenic acid, or do so at a very slow rate. Whether such 
penicillins will be  effective antibacterial agents remains  uncertain,  however, 
as it is conceivable that the antibacterial activity of penicillin is a consequence 
of degradation to penicillenic acid in the bacterial cell. 
Although the data obtained by skin-testing guinea pigs and human subjects 
with conjugates are reasonably clear and consistent, the injection of penicillin 
itself has highly variable consequences. Intradermal injection of penicillin has, C.  W.  PARKER,  J.  SHAPIRO,  M.  KERN,  AND  H.  N.  EISEN  835 
for example, given erratic  responses when used in efforts aimed at detecting 
human penicillin  allergy (for example, see reference 12). Since polyfunctional 
conjugates are required for elicitation of wheal-and-erythema responses (4, 5), 
it is likely that  in  those instances where penicillin  itself has  elicited such a 
skin reaction it is  a  consequence of penicillenic  acid  (which  presumably can 
form rapidly in vivo, or may even be present in the solution injected) coupling 
with skin protein to form the required conjugates. Considerations of this type 
probably account also for some of the apparent discrepancies  between systemic 
reactions to penicillin  therapy and positive wheal-and-erythema responses  to 
penicilloyl-polylysine. Although 40 per cent of individuals with positive wheal- 
and-erythema responses to penicilloyl-polylysine who were treated with peni- 
cillin  exhibited systemic allergic  reactions,  the majority of these individuals 
did not (Table VIII). The failure to observe systemic reactions more frequently 
in this  group may be ascribed to one or more of the following  possibilities: 
(a) the level of humoral antibody may have been too low; (b) the rate of deg- 
radation  of penicillin  to penicilleuic  acid may have been too slow to permit 
the accumulation of polyfunctional protein conjugate at a  sufficient  rate;  (c) 
penicillin  itself, and also free penicilloic acid formed by hydrolysis of penicillenic 
acid, are probably specific inhibitors of the reaction between penicilloyl-protein 
conjugates and anti-peuicilloyl antibody (see reference 6).  Thus the outcome 
of the injection of penicillin  in respect to the development of local or systemic 
allergic  responses  probably reflects  the balance of a series of competitive reac- 
tions; i.e.,  diffusion  and excretion of penicillin,  rearrangement  of penicillin  to 
penicillenic  acid, hydrolysis of penicillenic  acid to penicilloic  acid,  coupling of 
penicillenic  acid to proteins, etc. Penicillenic  acid reacts rapidly with proteins 
and with water at physiologic pH values (1, 2, 6), and it is likely that the rate- 
limiting step in the formation of protein conjugates of any of the types dis- 
cussed herein is the rate of formation of penicillenic  acid from penicillin.  If the 
accumulation of protein conjugate is sufficiently slow to avoid rapid and ex- 
tensive complex formation with antibodies, then the conjugates may actually 
succeed in specifically  removing antibodies, particularly those of high affinity 
for  the  determinants  involved.  Hence  temporary  desensitization,  at  least 
to some extent, is actually an expected consequence of the administration  of 
therapeutic amounts of penicillin  to sensitive individuals,  whether or not im- 
mediate systemic responses are observed. We have, in fact, observed loss of skin 
reactivity to penicilloyl-polylysine in a few of the sensitive patients who were 
given penicillin  in therapeutic amounts. 
The fact that some subjects with histories of previous penicillin  allergy have 
given negative skin responses to intradermal injection of penicilloyl-polylysine 
and to penicillenate S-HSA (Table VII) may be ascribed to one or more of the 
following possibilities: (a) the determinants involved in the previous systemic 
allergic reactions may have been generically different from those in the present 836  PENICILLIN ALLERGY  IN  HUMAN"  BEINGS 
skin test reagents; (b)  humoral antibody levels may have declined below the 
threshhold value, either as a consequence of the long time elapsed from previous 
therapy, or as a consequence of desensitization by the penicillin therapy itself 
(see  above);  (c)  the  threshold  concentration of  antibody  required for  some 
systemic allergic reactions might be lower than the threshold required for the 
wheal-and-erythema response;  (d)  the  variable  R  substituents  of  different 
types of penicillin may make a significant contribution to the interaction with 
antibody,  and  may have  been  different in  the  therapeutically administered 
penicillin which  evoked a  previous  systemic reaction  and in  the  conjugates 
used for skin testing in the present study; (e) previous histories in some sub- 
jects may have been inaccurate or inaccurately interpreted. 
Although the preliminary results so far obtained are encouraging, it is obvious 
that  considerably more  information is  required  before penicilloyl-polylysine 
can be considered a  safe and practical skin-test reagent for the diagnosis of 
penicillin allergy. Thus  if the  variable R  substituent of penicillins makes a 
significant contribution to the specific interaction with antibody, a correspond- 
ingly large number of conjugates, differing from each other in respect to the R 
group, will ultimately be required. Moreover, although our preliminary findings 
have failed to reveal antibody formation as a consequence of injecting guinea 
pigs with penicilloyl-polylysines in Freund's adjuvant, it is obvious both from 
the limited sensitivity of the assay used (passive cutaneous anaphylaxis; see 
reference 4)  and from differences in immune responses between humans and 
guinea pigs, that the immunogenic potency of penicilloyl-polylysine will have 
to be extensively evaluated in man. 
The successful transfer, in one instance, of cutaneous reactivity to penicilloyl- 
polylysine with a serum globulin fraction of a penicillin-sensitive individual is 
noteworthy. In this experiment (Table VI), the wheal-and-erythema response 
to penicilloyl-polylysine  was elicited 5 days after passive sensitization  of the skin 
site. Hence, the specific globulin involved may correspond to the class of human 
antibodies known as "reagins." In fact, quite aside from their implications for 
the practical detection of penicillin allergy, the findings reported herein seem to 
us particularly significant because they give promise of making available  an 
immune system which may permit the isolation and characterization of those 
human antibodies ("reagins") which seem to have distinctive features in respect 
to skin sensitivity. 
The results of the present study, taken as a whole (see also references 1, 4-6, 
13,  14), provide gratifying confirmation that the principles established in the 
study of hypersensitivity to simple chemicals in laboratory animals are appli- 
cable also to drug hypersensitivity in man. 
SUM~RY 
Multifunctional derivatives of penicillenic acid are effective elicitors of wheal- 
and-erythema skin responses in humans allergic to penicillin. Of the effective C.  W.  PARKER, J.  SHAPIRO,  ~[.  KERN,  AND  H.  N.  EISEN  837 
derivatives,  penicilloyl-polylysines are  particularly  attractive  as  skin  test 
reagents because they appear to be incapable of inducing antibody formation. 
The skin responses are specifically inhibitable in most instances by homologous 
unifunctional haptens.  The peniciUenic  acid derivatives which appear  to be 
determinants of human allergic reactions to penicillin are: penicilloyl, penicil- 
lenate, and groups of the penamaldate-penilloaldehyde type. Of these, the most 
significant appears to be the penicilloyl-lysyl  determinant. 
Note Added in Proof.--Since submission of this and the accompanying papers (4, 6), 
Levine and Ovary (J. Exp. Meg.,  1961, 114, 875), have reported positive wheal-and- 
erythema responses induced with penicilloyl-HTG (and inhibited with ~-peniciUoyl- 
aminocaproate) in 3 penicillin-sensitive human subjects. In I of 5 sera from peniciUin- 
sensitive  humans,  passive  cutaneous  anaphylaxis  reactions  were  elicited  with  a 
penicilloyl-protein and inhibited  with ~-penicilloyl-aminocaproate. 
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